Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen reports 'striking' results for Xgeva in delaying prostate cancer bone metastases

This article was originally published in Scrip

Executive Summary

In reporting full results of its study 147, Amgen on 17 May not only confirmed that its 120mg dosage form of denosumab, known as Xgeva, improved median bone metastasis-free survival by 4.2 months in men with castrate-resistant prostate cancer (CRPC) versus placebo – the first time a bone-targeted drug has delayed the spread of prostate cancer to the bones – but new data showed the drug also significantly delayed the time to first bone metastasis and the time to symptomatic, or painful, bone metastasis.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012958

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel